Evidence has demonstrated that administration of anti-TNF mAb (e.g., infliximab) could facilitate maturation of CD68+CD206+ macrophages in the intestinal mucosa of IBD patients and concomitantly inhibiting T cell proliferation [6, 188]. Here, TNF is linked to inflammatory bowel disease.